{"ticker": {"uuid": "d3eebfdd-3102-40c3-812c-c4fc1f64d7c4", "symbol": "PAR", "name": "Paradigm Biopharmaceuticals Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Paradigm Biopharmaceuticals (ASX: PAR) Returns to the Spotlight Ahead of Key Phase 3 Trial Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNeWlWYzRRN0RTZmtYQ3pHeFNNaW9QWVU1RllUOGZyMXZNVF9BcEI4MDhNaFJEZUhEeEV4ZzV5VDFvZENKcUlmRnRac0d5RmNIQVRhY2d3Z3A1Q2x3eXd3dnN5cEdZV2o5MkdhNUMyam83Umk3Unp6LW1fVkE2UkZpZFpvX2RaSkgyWW9GXzlHZHFfVy05MmJiR2F0Mkc0S3oyQkZLR2c2cmpZWkc3RnMzNVllOUpXUk55aHQzOG5RZU9lOW9LTU9YdElVYmtnSE9wcXc?oc=5", "source_name": "Kalkine", "published_at": "2026-07-17T07:17:00+00:00", "published_display": "17 Jul 2026 07:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals (ASX:PAR) Surges 9.38%: What's Driving the Biotech's Big Day?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPa2taU2h1cUwwb21hZ09GRXpnN2o4bExlMXdQaWt3UGdpZ1hIZ2FBQWxvQmZ0Ql9Pb3BaaEpSS1VNaDBnQ3VWVE85Q1A3VFhTOFhMM2FuZS14dmNZQy16c3pvdE91Z1VzMFBRWWdKVVhzX1NUY1ljYzNmV0dnUG1vZXp5QmtvcnlKVGpyeXFnNGkyLVc4eFRBekd0VHJObWpISzJvMEdTdGpiY3d4SUFLMUljbV9HUkVRcThN?oc=5", "source_name": "Kalkine", "published_at": "2026-07-16T10:31:00+00:00", "published_display": "16 Jul 2026 10:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals Issues 3 Million Convertible Notes at USD $1.00 Each, Advancing US$27M Phase 3 OA Trial Funding", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQemJjU2FnMXdLWEZzRks2LVZWMy1Qb0NMel96Nzd4eDlxWVdLcmN5TU5iMEVZSl82dElWN0FMajhNaVB3ZjNYOExXSEFQZjIycjhGcVlSaHR3aXFFSnJqbFVONURCQXQ1a2ppc19aV1hUUFpHVUZwUEktOWhZdnlLUG83ZDdsa1JsTW9iUXc3R0VFc1lRQUlvblJKeUlNS0VrX0dlN01ZQUE4TndnRnBIOG9iVzFhQW1sd0hzSlFUTVk5Y2kwUFppa1pFa282QTNQcmJha0tOLTljVl9RQTF4cDJLNUhfb0RDR19TMFJHek5qcVU?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T03:28:09+00:00", "published_display": "13 Jul 2026 03:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Paradigm Biopharmaceuticals Ltd. \u2013 ASX:PAR", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQanE5ZlEyZFo1eFpRN0Y1WS0wUjhWaVRsaU83MUc0OW9hNldoQmdpRHVaREtkUHI0NjZnZEZhTUEtSkJpR0NoZXNPTEtBUmkwbTlkN296ZHpGZjhWZFQ2N0M2TWtMTzRwNHdFOUppTHFnSF9XMUVDRUVyeVAwcTdKYkFpVERzVFlERGJ4dU14dDVMUUYxS3RRNHlCWjY3MzdVYTFFQi1B?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T14:54:10+00:00", "published_display": "10 Jul 2026 14:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals (ASX:PAR) Is Gaining Investor Attention \u2014 Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPbHJKb0dITjV2YWFXenFFTXJnQlZuV2lMd2lTOERTcUwwXzdIeVZzVWFVSjZrTnplTU9MZlZPOUlVUnJ6ZE9wNEdPRHYxaEJ5d2I2Ny01eUNjdXUzdFktUG82R3BSLTlPZ1daMUplYUdyRVRWZTdLMElLQVZtcGkycnBLZm8wRVBmaGtVbGlaQnRtcjd4NXI2Y2tVNDE4Q3kyZjZYVUdmc0Npby14VFZxdVctSQ?oc=5", "source_name": "Kalkine", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals updates market on director Paul Rennie\u2019s expanded option holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxQUVJsUEJac3pVSWY4WDhVb1hTcWlsSFFOUGJ3VVU2a3hmYnVpWjFkbXktZlRrMUJMa1VLZEc1em9hY3lfSVNYMTJmZngwdG9NbnlvcGNEd2hGUTVKeVVfWVI4V011UTcyWnRZM09hcU0yaDk0REdhOFptanhzNjFFdmVQR19jZjY3SWxuVFhjeWJyME9ob291ZVJtWXpDbTZGVzMyeXhHeW1RZGlZalhYODNZdDVQUFhLallNb2g5SE9PLVBBTzR0LWlhNmlGWGFiOHFibGNjN3NyTXl4WFNBRUUxZVJfVFg2a2Ewb056UEhwN2VRMzhSb0N2bi1rV3lBTV80?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals (ASX:PAR) Gains as Biotech Traders Watch the Next Catalyst", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQR2VTUG83elptU0VibEZlSEFDWVRXSWd3eDN1NkNYWVlhaTYzQlpxZVBWUHJKM05KOU1VR1hZN195NEZzUE5HbFdxRlFWcTVJMWFHWnROWmphcWFTMEtsMnp0Q21tNzJLNnVWMFk2LXVHd0kyMGRMcV9tVE9XbXhiSWYzb0tCOGxTVmpUR2lTWGpsTUJyUnliWDZQUjI4d3piZGdBU2hPX19iZExIQm5lYW9aelFibEFKcmlNbU1LUW5IUQ?oc=5", "source_name": "Kalkine", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Market Sentiment Around Loss-Making Paradigm Biopharmaceuticals Limited (ASX:PAR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQYlI3Y1l4TDZjYkQzZS1QRXBwS1gxXy04QkJkS3RjRUlTRGhkTmNqWUtkd1RzRnVqajJoMFR5RDRHb0pTRDBhME9hcWhNN0JiM3A4aW03YVRBS2ZReEFES0I3Z1M3TGNQN01SUDBuV2czZ29OYTdrX1lQa2N3RXlCV201OFFVYWJDYkt3dnhnTDk2THJFbGFROXdROGp4ZVRFZUg0Q3RvMA?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals raises $14M in upsized placement, launches SPP", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPeDYtNTdNSXp6Nmtzc2JDcTlDdERoYm8tZXpjOGVDZVYzY2lFNmdvOS1ZQ19RUEM1WVZmU3ZKekpyck1ydUg3bDlOdjd6LUEyQ21nb1JFQ2Q2eGZmRDNyRnF6b1dZa0MzbGRjYklpaFdWX2dFTmNhTWJTbkRVX2FubEt6V1FYaWdrMXR4d2ZzXzFmdzg3RFhLNHRhWjA1NUVIMlRqYl9iOGZFYjFfTHQ0NTFKUE9IY29tbWJGUHAyWGMtZnhLMTlBOEhtUjI4YUlRbGp0TGNZTDdGYldvRmR3?oc=5", "source_name": "Proactive financial news", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health Check: Paradigm holders go for extra fries in super-sized placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxNZUNzYk0wUG1zaDREQzRXdUJ0WVlPUzFmdDVobEE1eEZmY0JiNDZ4Vjlsd0N1a2NXaWZfaHRCLURRcGQyMnJGYW53VGotckxfb0Z0d3BlQ25xVURRcHZCbExMNUJrS1RBVlExa0RkT2VmWFpCYVozM1FkTEdBUW1sMlpiNzNuRUVPLVZvNVJlRXc3YkZBZW5kMVphcHo3UFJfOUZTN0RrcG9hMV9rYmRZWGJValcyczB1bjBtdWhKZXl2STNBckdjWGVUVmliaGJva1ROMHFDX2szYnByOWRVa0NkeUFKX2FLUGhDZTNZZlhmQ0p2M29WUzRzT0dJYUlwVW5QV2tTaXBqU0dhN2lueVE2YXRPUQ?oc=5", "source_name": "Stockhead", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxQSFJlT2RrY1NfZmI1dXpOU0luVHR5ODFOdDRVcFZnUXZIdHE2d2FfdjVmcVpkc0pBengtYk1HYzduTnkyZFM4TTdVTWwxTy0wUTZ3dWs3cTJVUENYMWtUcmcwY3NqOHdDZS1ld01FYmdIYng0UjVFVjVtdVI1Q3BDTzByd1FjQnotV1lsSjRKVkxZeWhNWVRTczVVYlkxUnZoU01ZMGkyQXdOUU9VWkQxVGU3RUFPNFRtaDVVb1g5Q3gwSFBmLWt6cFhDRDNwSUR6VWZlWlpzemMzOWRpRmJaRWpkZ0tqd3pZZ0tMaXI1RUVtV0l6dlo5dtIB_gFBVV95cUxOd2VPdjR6akNOOVBHYW5GWS1udEpqSEZ2NE9sV3lMOF9UN0ZsM2xzRXRGZk9fMk9IYWlxWGkxV2pxWnVRUThnOFdCdTVLcWl3LXd0RUdpMzZHZEZzSGFSZEYxdEVONlVCYk9heXRhWHVnLVB4QU9RZ2pkTi0zVkg3OVJ2QUtfdEQ4WER3S1FuLURTaTVIWGFEN0M4T0ZSSnVUcUx2SzQwbklEZWwtZTJlbjRRdHhzaEZNYmo1ajNvdVNXOWZ0SlR1ODl4Z2pyb3JrcmRWWnFYWTZvZ2ZmeW9fWFZkMTg2eDR6RDB0ZWM2aG1QemNTak5NWXJiYkhqZw?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals (ASX: PAR) Ended the Session Up: What Investors Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPeHVZTTdpXzVVNms1S1FMVXZKQXJXS2NNbXBTNlcxLXl5SHRNSzg3ZU1KQjlQekFsWUo4Y01MaWJJNkxBbHA2M1A0QzA3aDJuMzBucGJNd3cwOGZOcUNJcUVWRFR3ZlJOaWtwSThNTDdPSGlaTHliZ0hRT0I2OWtMMExKU054UHJ4dnU5dzZPSDA3OVF6dVUyMFNXUTZhZ2NHMWNEN3JqSHBGZWVxQkpMSmxhNXBkV2ZQVFEtWG9RSQ?oc=5", "source_name": "Kalkine", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Paradigm Biopharmaceuticals' (ASX:PAR) Leadership Vision Drive Long-Term Strategic Value?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-24T07:00:00+00:00", "published_display": "24 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals (ASX:PAR): Assessing Valuation as Investor Focus Builds Ahead of Ignite Summit Presentation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals enters critical phase with global osteoarthritis program", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQSHItQWZjeXF4NWxPdEZ4LVFlQmhvQW5zdklvWEFNQnpYYUhpSkFMdFJIcTY1LW1ycUxsbzZVQXh6TWpYSWg0WHBRY1NxOEhfUThmbDdKRDVjT0xFSk45VTBsSEZJci1sbUVvWmZCQk1zaFhkNHRmeUVOYlM5Z3Q4Y0tnMklCSGFUVnNybzhQeUc0bzMwRlRPRDVzdXI4S01sU0lPVkw1VEN0YWhZVnZZT2Q4VTNPZUFtcVZlVA?oc=5", "source_name": "BiotechDispatch", "published_at": "2025-08-31T07:00:00+00:00", "published_display": "31 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm eyes $110m raise with loyalty offer", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Australian", "published_at": "2025-02-03T08:00:00+00:00", "published_display": "03 Feb 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals\u2019 flagship drug Zilosul will be in Phase 3 in 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE45X0JMa0JJWHFMNnhjYmR1RXM4eXdTQ1pvRjdxVFdtOUpMUWItWUx3ZThLRHlLQ2UxWHFWSDdWc0t5U1FIdk9QUzJGOTJMeV8zb2tPUEZpVjVRMmxsWlRHbkpZYWFOTWFEWEYwU1lUZ1Nvdw?oc=5", "source_name": "Stocks Down Under", "published_at": "2025-01-23T08:00:00+00:00", "published_display": "23 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNdE8xdHZ3RWRHOXZKbml4VWpMa0RqdEhwUDNUWmY4aXNLUEFjaDlQUnFRMzI4N1VkYW9ETFFZSkRfWndsanRRM2t0VmFQeEtMU0RyOUFHSDZZNnhKcFJNdVlvQTRzVzRPRHpZZF9jcWt4aGRydDJXN2RyQnN3QXIwWktEcDJPbFh4dTYzMG05RUduVndSLV9OZ04wcURTSTFia2xkWjFJQVpIMU1sZFJzaFdwbmZYZUp6aUxZazAzWGdqRllGdEhrbDJoMA?oc=5", "source_name": "Stocks Down Under", "published_at": "2024-09-06T07:00:00+00:00", "published_display": "06 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Paradigm Biopharmaceuticals (ASX: PAR) Returns to the Spotlight Ahead of Key Phase 3 Trial Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNeWlWYzRRN0RTZmtYQ3pHeFNNaW9QWVU1RllUOGZyMXZNVF9BcEI4MDhNaFJEZUhEeEV4ZzV5VDFvZENKcUlmRnRac0d5RmNIQVRhY2d3Z3A1Q2x3eXd3dnN5cEdZV2o5MkdhNUMyam83Umk3Unp6LW1fVkE2UkZpZFpvX2RaSkgyWW9GXzlHZHFfVy05MmJiR2F0Mkc0S3oyQkZLR2c2cmpZWkc3RnMzNVllOUpXUk55aHQzOG5RZU9lOW9LTU9YdElVYmtnSE9wcXc?oc=5", "source_name": "Kalkine", "published_at": "2026-07-17T07:17:00+00:00", "published_display": "17 Jul 2026 07:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals (ASX:PAR) Surges 9.38%: What's Driving the Biotech's Big Day?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPa2taU2h1cUwwb21hZ09GRXpnN2o4bExlMXdQaWt3UGdpZ1hIZ2FBQWxvQmZ0Ql9Pb3BaaEpSS1VNaDBnQ3VWVE85Q1A3VFhTOFhMM2FuZS14dmNZQy16c3pvdE91Z1VzMFBRWWdKVVhzX1NUY1ljYzNmV0dnUG1vZXp5QmtvcnlKVGpyeXFnNGkyLVc4eFRBekd0VHJObWpISzJvMEdTdGpiY3d4SUFLMUljbV9HUkVRcThN?oc=5", "source_name": "Kalkine", "published_at": "2026-07-16T10:31:00+00:00", "published_display": "16 Jul 2026 10:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals Issues 3 Million Convertible Notes at USD $1.00 Each, Advancing US$27M Phase 3 OA Trial Funding", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQemJjU2FnMXdLWEZzRks2LVZWMy1Qb0NMel96Nzd4eDlxWVdLcmN5TU5iMEVZSl82dElWN0FMajhNaVB3ZjNYOExXSEFQZjIycjhGcVlSaHR3aXFFSnJqbFVONURCQXQ1a2ppc19aV1hUUFpHVUZwUEktOWhZdnlLUG83ZDdsa1JsTW9iUXc3R0VFc1lRQUlvblJKeUlNS0VrX0dlN01ZQUE4TndnRnBIOG9iVzFhQW1sd0hzSlFUTVk5Y2kwUFppa1pFa282QTNQcmJha0tOLTljVl9RQTF4cDJLNUhfb0RDR19TMFJHek5qcVU?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T03:28:09+00:00", "published_display": "13 Jul 2026 03:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Paradigm Biopharmaceuticals Ltd. \u2013 ASX:PAR", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQanE5ZlEyZFo1eFpRN0Y1WS0wUjhWaVRsaU83MUc0OW9hNldoQmdpRHVaREtkUHI0NjZnZEZhTUEtSkJpR0NoZXNPTEtBUmkwbTlkN296ZHpGZjhWZFQ2N0M2TWtMTzRwNHdFOUppTHFnSF9XMUVDRUVyeVAwcTdKYkFpVERzVFlERGJ4dU14dDVMUUYxS3RRNHlCWjY3MzdVYTFFQi1B?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T14:54:10+00:00", "published_display": "10 Jul 2026 14:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals (ASX:PAR) Is Gaining Investor Attention \u2014 Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPbHJKb0dITjV2YWFXenFFTXJnQlZuV2lMd2lTOERTcUwwXzdIeVZzVWFVSjZrTnplTU9MZlZPOUlVUnJ6ZE9wNEdPRHYxaEJ5d2I2Ny01eUNjdXUzdFktUG82R3BSLTlPZ1daMUplYUdyRVRWZTdLMElLQVZtcGkycnBLZm8wRVBmaGtVbGlaQnRtcjd4NXI2Y2tVNDE4Q3kyZjZYVUdmc0Npby14VFZxdVctSQ?oc=5", "source_name": "Kalkine", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals updates market on director Paul Rennie\u2019s expanded option holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxQUVJsUEJac3pVSWY4WDhVb1hTcWlsSFFOUGJ3VVU2a3hmYnVpWjFkbXktZlRrMUJMa1VLZEc1em9hY3lfSVNYMTJmZngwdG9NbnlvcGNEd2hGUTVKeVVfWVI4V011UTcyWnRZM09hcU0yaDk0REdhOFptanhzNjFFdmVQR19jZjY3SWxuVFhjeWJyME9ob291ZVJtWXpDbTZGVzMyeXhHeW1RZGlZalhYODNZdDVQUFhLallNb2g5SE9PLVBBTzR0LWlhNmlGWGFiOHFibGNjN3NyTXl4WFNBRUUxZVJfVFg2a2Ewb056UEhwN2VRMzhSb0N2bi1rV3lBTV80?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals (ASX:PAR) Gains as Biotech Traders Watch the Next Catalyst", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQR2VTUG83elptU0VibEZlSEFDWVRXSWd3eDN1NkNYWVlhaTYzQlpxZVBWUHJKM05KOU1VR1hZN195NEZzUE5HbFdxRlFWcTVJMWFHWnROWmphcWFTMEtsMnp0Q21tNzJLNnVWMFk2LXVHd0kyMGRMcV9tVE9XbXhiSWYzb0tCOGxTVmpUR2lTWGpsTUJyUnliWDZQUjI4d3piZGdBU2hPX19iZExIQm5lYW9aelFibEFKcmlNbU1LUW5IUQ?oc=5", "source_name": "Kalkine", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Market Sentiment Around Loss-Making Paradigm Biopharmaceuticals Limited (ASX:PAR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQYlI3Y1l4TDZjYkQzZS1QRXBwS1gxXy04QkJkS3RjRUlTRGhkTmNqWUtkd1RzRnVqajJoMFR5RDRHb0pTRDBhME9hcWhNN0JiM3A4aW03YVRBS2ZReEFES0I3Z1M3TGNQN01SUDBuV2czZ29OYTdrX1lQa2N3RXlCV201OFFVYWJDYkt3dnhnTDk2THJFbGFROXdROGp4ZVRFZUg0Q3RvMA?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals raises $14M in upsized placement, launches SPP", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPeDYtNTdNSXp6Nmtzc2JDcTlDdERoYm8tZXpjOGVDZVYzY2lFNmdvOS1ZQ19RUEM1WVZmU3ZKekpyck1ydUg3bDlOdjd6LUEyQ21nb1JFQ2Q2eGZmRDNyRnF6b1dZa0MzbGRjYklpaFdWX2dFTmNhTWJTbkRVX2FubEt6V1FYaWdrMXR4d2ZzXzFmdzg3RFhLNHRhWjA1NUVIMlRqYl9iOGZFYjFfTHQ0NTFKUE9IY29tbWJGUHAyWGMtZnhLMTlBOEhtUjI4YUlRbGp0TGNZTDdGYldvRmR3?oc=5", "source_name": "Proactive financial news", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health Check: Paradigm holders go for extra fries in super-sized placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxNZUNzYk0wUG1zaDREQzRXdUJ0WVlPUzFmdDVobEE1eEZmY0JiNDZ4Vjlsd0N1a2NXaWZfaHRCLURRcGQyMnJGYW53VGotckxfb0Z0d3BlQ25xVURRcHZCbExMNUJrS1RBVlExa0RkT2VmWFpCYVozM1FkTEdBUW1sMlpiNzNuRUVPLVZvNVJlRXc3YkZBZW5kMVphcHo3UFJfOUZTN0RrcG9hMV9rYmRZWGJValcyczB1bjBtdWhKZXl2STNBckdjWGVUVmliaGJva1ROMHFDX2szYnByOWRVa0NkeUFKX2FLUGhDZTNZZlhmQ0p2M29WUzRzT0dJYUlwVW5QV2tTaXBqU0dhN2lueVE2YXRPUQ?oc=5", "source_name": "Stockhead", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxQSFJlT2RrY1NfZmI1dXpOU0luVHR5ODFOdDRVcFZnUXZIdHE2d2FfdjVmcVpkc0pBengtYk1HYzduTnkyZFM4TTdVTWwxTy0wUTZ3dWs3cTJVUENYMWtUcmcwY3NqOHdDZS1ld01FYmdIYng0UjVFVjVtdVI1Q3BDTzByd1FjQnotV1lsSjRKVkxZeWhNWVRTczVVYlkxUnZoU01ZMGkyQXdOUU9VWkQxVGU3RUFPNFRtaDVVb1g5Q3gwSFBmLWt6cFhDRDNwSUR6VWZlWlpzemMzOWRpRmJaRWpkZ0tqd3pZZ0tMaXI1RUVtV0l6dlo5dtIB_gFBVV95cUxOd2VPdjR6akNOOVBHYW5GWS1udEpqSEZ2NE9sV3lMOF9UN0ZsM2xzRXRGZk9fMk9IYWlxWGkxV2pxWnVRUThnOFdCdTVLcWl3LXd0RUdpMzZHZEZzSGFSZEYxdEVONlVCYk9heXRhWHVnLVB4QU9RZ2pkTi0zVkg3OVJ2QUtfdEQ4WER3S1FuLURTaTVIWGFEN0M4T0ZSSnVUcUx2SzQwbklEZWwtZTJlbjRRdHhzaEZNYmo1ajNvdVNXOWZ0SlR1ODl4Z2pyb3JrcmRWWnFYWTZvZ2ZmeW9fWFZkMTg2eDR6RDB0ZWM2aG1QemNTak5NWXJiYkhqZw?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals (ASX: PAR) Ended the Session Up: What Investors Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPeHVZTTdpXzVVNms1S1FMVXZKQXJXS2NNbXBTNlcxLXl5SHRNSzg3ZU1KQjlQekFsWUo4Y01MaWJJNkxBbHA2M1A0QzA3aDJuMzBucGJNd3cwOGZOcUNJcUVWRFR3ZlJOaWtwSThNTDdPSGlaTHliZ0hRT0I2OWtMMExKU054UHJ4dnU5dzZPSDA3OVF6dVUyMFNXUTZhZ2NHMWNEN3JqSHBGZWVxQkpMSmxhNXBkV2ZQVFEtWG9RSQ?oc=5", "source_name": "Kalkine", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Paradigm Biopharmaceuticals' (ASX:PAR) Leadership Vision Drive Long-Term Strategic Value?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-24T07:00:00+00:00", "published_display": "24 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals (ASX:PAR): Assessing Valuation as Investor Focus Builds Ahead of Ignite Summit Presentation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals enters critical phase with global osteoarthritis program", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQSHItQWZjeXF4NWxPdEZ4LVFlQmhvQW5zdklvWEFNQnpYYUhpSkFMdFJIcTY1LW1ycUxsbzZVQXh6TWpYSWg0WHBRY1NxOEhfUThmbDdKRDVjT0xFSk45VTBsSEZJci1sbUVvWmZCQk1zaFhkNHRmeUVOYlM5Z3Q4Y0tnMklCSGFUVnNybzhQeUc0bzMwRlRPRDVzdXI4S01sU0lPVkw1VEN0YWhZVnZZT2Q4VTNPZUFtcVZlVA?oc=5", "source_name": "BiotechDispatch", "published_at": "2025-08-31T07:00:00+00:00", "published_display": "31 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm eyes $110m raise with loyalty offer", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Australian", "published_at": "2025-02-03T08:00:00+00:00", "published_display": "03 Feb 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals\u2019 flagship drug Zilosul will be in Phase 3 in 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE45X0JMa0JJWHFMNnhjYmR1RXM4eXdTQ1pvRjdxVFdtOUpMUWItWUx3ZThLRHlLQ2UxWHFWSDdWc0t5U1FIdk9QUzJGOTJMeV8zb2tPUEZpVjVRMmxsWlRHbkpZYWFOTWFEWEYwU1lUZ1Nvdw?oc=5", "source_name": "Stocks Down Under", "published_at": "2025-01-23T08:00:00+00:00", "published_display": "23 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNdE8xdHZ3RWRHOXZKbml4VWpMa0RqdEhwUDNUWmY4aXNLUEFjaDlQUnFRMzI4N1VkYW9ETFFZSkRfWndsanRRM2t0VmFQeEtMU0RyOUFHSDZZNnhKcFJNdVlvQTRzVzRPRHpZZF9jcWt4aGRydDJXN2RyQnN3QXIwWktEcDJPbFh4dTYzMG05RUduVndSLV9OZ04wcURTSTFia2xkWjFJQVpIMU1sZFJzaFdwbmZYZUp6aUxZazAzWGdqRllGdEhrbDJoMA?oc=5", "source_name": "Stocks Down Under", "published_at": "2024-09-06T07:00:00+00:00", "published_display": "06 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 90, "total_relevant": 18, "sentiment_summary": {"positive": 5, "negative": 0, "neutral": 13, "score": 55, "total": 18, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 93, "events": [{"event": "general", "label": "Market update", "weight": 9.35, "count": 17}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.17, "latest_week": "2026-07-10", "one_week_move": -2.9, "four_week_move": 13.3, "twelve_week_move": -24.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.398415, "market_dynamics_buy_signal": false, "relative_strength": -40.722608, "fair_value_gap": -52.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.6235, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.9% over one week, +13.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 69, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Kalkine", "count": 6}, {"label": "simplywall.st", "count": 3}, {"label": "Stocks Down Under", "count": 2}, {"label": "TradingView", "count": 1}, {"label": "The Globe and Mail", "count": 1}, {"label": "Market source", "count": 1}, {"label": "Proactive financial news", "count": 1}, {"label": "Stockhead", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 18}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 17}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "93/100 classification confidence."}, {"label": "Company focus", "value": "18", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.9% over one week, +13.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Paradigm Biopharmaceuticals (ASX: PAR) Returns to the Spotlight Ahead of Key Phase 3 Trial Milestone"}], "updated_at": "2026-07-18T04:19:35.452230+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}